TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The American Gastroenterological Association published guideline updates covering MASLD, alcohol-associated liver disease and cancer surveillance. Separately, Mirum Pharmaceuticals said the phase III portion of its AZURE-1 trial of investigational brelovitug for chronic hepatitis D met its primary endpoint; detailed trial results were not provided in the source report.
The American Gastroenterological Association has published updated guidance on metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease and surveillance for pancreatic cysts and liver cancer in older adults, while Mirum Pharmaceuticals reported that a phase III trial of investigational brelovitug met its primary endpoint in chronic hepatitis D. The developments were included in an October 1 gastroenterology roundup; the available report does not provide the full guideline recommendations or detailed trial results.
The AGA guideline updates address several areas of clinical practice: management of MASLD and alcohol-associated liver disease, surveillance of pancreatic cystic lesions, and hepatocellular carcinoma (HCC) surveillance in older adults. The source report identifies the updates and points to publication in Clinical Gastroenterology and Hepatology, but does not describe specific screening intervals, treatment choices or patient eligibility criteria.
In a separate development, the phase III portion of AZURE-1, testing brelovitug in people with chronic hepatitis delta virus (HDV), met its primary endpoint, according to drugmaker Mirum Pharmaceuticals. The company said the endpoint involved a virologic response and normalization of alanine aminotransferase (ALT), a liver enzyme. The report does not give the size of the treatment effect, the number of participants, safety findings or a comparison with a control group.
The roundup also noted research relevant to treatment choices in ulcerative colitis (UC). A five-year analysis in JAMA Network Open found that patients who began vedolizumab as their first-line treatment spent more time with corticosteroid-free disease than patients who began a TNF inhibitor. That is an observational comparison as described in the report; it does not establish that vedolizumab is the best first-line option for every patient. The headline’s question about first-line UC treatment is not answered by a formal guideline recommendation in the supplied material.
Guidance and Evidence for Liver Care
The AGA updates matter because they address decisions clinicians make about liver disease management and surveillance for serious conditions, including HCC. Guidance can help standardize care, but readers cannot determine what has changed or how recommendations apply to a particular patient from the roundup alone. The full documents are needed for details such as risk groups, testing schedules and exceptions.
The AZURE-1 result is an important development for an area with substantial unmet treatment needs, but the announcement is an interim account of trial performance rather than a complete evidence package. Meeting a primary endpoint indicates that a prespecified trial goal was reached, as described by the company; it does not by itself establish the size of benefit, how benefits compare with existing care, or whether regulators will authorize the medicine.
The UC analysis may inform discussion of initial biologic treatment, particularly the goal of controlling disease while avoiding prolonged corticosteroid use. However, a five-year cohort comparison can be affected by differences between patients and treatment decisions. It should be read as evidence about outcomes in the studied group, not as proof of a universal ranking among UC medicines.
liver disease surveillance test kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Other Guidance and Treatment Findings
The October 1 roundup covered a broader set of gastroenterology and hepatology developments. European societies issued guidance concerning resmetirom or semaglutide for metabolic dysfunction-associated steatohepatitis, while U.S. societies, including the AGA, offered consensus recommendations on serrated polyposis syndrome. These are separate publications from the AGA updates on liver disease and surveillance described above.
The report also summarized retrospective data in TNF-exposed UC patients that favored upadacitinib over vedolizumab for effectiveness, but associated upadacitinib with more adverse events. That finding concerns a different patient group and study design from the five-year first-line vedolizumab analysis. Taken together, the reports highlight why treatment comparisons depend on prior therapies, outcome measures and safety considerations, rather than supporting one option for all UC patients.
For chronic HDV, the AZURE-1 announcement concerns brelovitug, which the source identifies as investigational. The report provides no information on regulatory review, availability or the full clinical dataset, so the endpoint news should not be confused with an approval or a change in treatment guidance.
“The phase III portion of AZURE-1 met its primary endpoint of virologic response and alanine aminotransferase normalization.”
— Mirum Pharmaceuticals, as reported in the MedPage Today roundup
hepatocellular carcinoma screening ultrasound
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Data and Guidance Details Pending
The source material does not include the AGA documents’ exact recommendations, the populations covered, or the evidence grades behind them. It is also unclear whether the updates change existing practice or clarify prior advice. Readers need the full publications to assess how the recommendations apply to specific patients and clinical settings.
For AZURE-1, the company-reported endpoint result is not accompanied here by participant numbers, response rates, effect size, duration of response, adverse-event data or trial design details. The report also does not say whether the full results have been presented or published, or whether Mirum has submitted or plans to submit an application to regulators. No conclusion about approval or routine use is supported by the supplied information.
The UC finding likewise leaves open how much of the difference reflects treatment itself versus patient selection or other factors. The summary does not provide the cohort size, absolute outcome rates or statistical estimates. The phrase “spent more time” cannot be converted into a treatment recommendation without reviewing the underlying analysis and its limitations.
ulcerative colitis first-line medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Full Publications and Trial Results
The next step for clinicians and readers is to review the full AGA guidance for its recommendations, supporting evidence and intended patient groups. Publication details identified in the roundup include Clinical Gastroenterology and Hepatology for the AGA updates. The underlying UC analysis and other studies should also be assessed in their original publications rather than relying on short summaries.
For brelovitug, further updates would need to provide the complete AZURE-1 findings, including efficacy measures, safety results and the trial’s design and follow-up. Any regulatory decision or change in treatment options remains unreported in the source material. Until such details are available, the confirmed development is limited to Mirum’s statement that the phase III portion met its primary endpoint.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the AGA update?
The AGA published updates on MASLD, alcohol-associated liver disease, surveillance for pancreatic cystic lesions and HCC surveillance in older adults. The source report does not provide the detailed recommendations.
What happened in the AZURE-1 trial?
Mirum Pharmaceuticals reported that the phase III portion of AZURE-1, testing investigational brelovitug for chronic hepatitis D, met its primary endpoint of virologic response and ALT normalization. Detailed results were not provided.
Is brelovitug approved for hepatitis D?
The supplied report identifies brelovitug as investigational and does not report an approval or regulatory decision. Meeting a trial endpoint is not the same as receiving authorization for use.
Does the UC study prove vedolizumab is the best first-line treatment?
No. The roundup says a five-year analysis found patients who started vedolizumab spent more time with corticosteroid-free disease than those starting a TNF inhibitor. It does not establish a best option for all patients, and the study details are not included in the summary.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
